comprehensive -WSS

comprehensive

author：comprehensive 2025-10-01 04:12:40 - browse：781

U.S. Sen. Bernie Sanders sets his hands on two chairs as two people set up a board displaying a "price of drugs" chart behind him — politics coverage from STAT — Sen. Bernie Sanders has used his leadership of a Senate committee to pressure drugmakers to lower their prices. Kevin Dietsch/Getty Images

WASHINGTON — Bernie Sanders is figuring out just how far bullying drugmakers can take him.

For more than a year, Sanders has used his perch atop the Senate health committee to haul the CEOs of pharmaceutical companies that make insulin, vaccines, and more before the panel with progressively more ambitious demands related to their pricing. After a few victories he’s claimed — experts say some credit is deserved, but the full story is a bit more complicated — he’s now progressed to demanding that Novo Nordisk cut its price for its novel, wildly popular diabetes and weight-loss drugs.

Sanders (I-Vt.) is testing the limits of the powers of a Senate chairman with little hope of advancing his policy agenda legislatively. He’s threatened subpoenas, held a prominent nominee hostage, and initiated investigations to get his way. It’s a sharp departure from the modest, bipartisan ambitions that more disciplined, discreet leaders of the committee have taken in years past, and sets the bar for how much can be accomplished using the full extent of the bully pulpit.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： How the drug

WSS

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

Wegovy improves function in certain heart failure patients

'Make People Better': The CRISPR babies story you probably don't know

What American doctors can learn from their Israeli counterparts

National associations that represent hospice owe an apology

As obesity drug market grows, telehealth companies court payers

explore

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

leisure time

Hepatitis C has a cure — but many Americans still lack access to it

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

The cancer drug shortage isn’t new — and neither are the solutions

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Stem cell treatment guidelines are released by FDA

Hepatitis C has a cure — but many Americans still lack access to it

How to make over

Walensky prepares to leave CDC — and Congress — behind

What American doctors can learn from their Israeli counterparts

entertainment

Medicaid rebukes states for mistakenly disenrolling children

What drug price negotiations mean for Medicare Part D

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

What drug price negotiations mean for Medicare Part D

Health officials lay out plans to cope with respiratory virus season

hotspot

hotspot

explore

leisure time